

Supplementary Table S1. PCR amplification and sequencing primers for noncoding conserved sequences

Region	Genomic location (nt)**	Primer sequence	Novel nucleotide variation*
a	107,071,320-107,071,430	F-CTTCCTAAATTCCTTAGGGAGTGAC R-GTTTCTTGAGGGCTAATCCTTATCT	
b	107,072,250-107,072,850	F-CATAATTAAGATGCTGCACTCTGTG R-CTAAAGGTTGTTATTTGGGAGAAT F-ATTATAATTTCTTTGGGTGGGAGAA R-ATTTAAGCTTCCCTTGACTCAATTT	
c	107,073,820-107,073,970	F-AGACCTATTAGGACGCTATTGCTTT R-ATTGTGCACATGTACCCTAAAACCTT	
d	107,080,160-107,080,210	F-GTACCTCAGTTGGAAATGCAGAAAT R-GATCACACCACTGCACTCTAGC	
e	107,081,605-107,081,635	F-AGCCTGGAACAATTTGATTTCTTA R-CAATCTTCGGAAGGAAGTCACTAT	
f	107,082,670-107,082,730	F-TTCCCCTTTACAAGTGTCATTA R-TCCTCAGTATATATGTGGCAACTGA	
g	107,084,175-107,084,290	F-AAAAACAAACAAACAAACACACAC R-AGAGAATCCAACCATTA R-AGAGAATCCAACCATTA R-AGAGAATCCAACCATTA	
h	107,085,630-107,086,150	F-ATAAATATGAGGCCAGGGTATAAGC R-ACCTTAGATTACTCACTTGGGCTTT F-AAGTGATGCATCTATTTCTTTGGAA R-AATAAGTCTGTCATGTATCTGGATG	Heterozygous g.-3521A>T in <i>cis</i> with p.M1T in family 242, 4/110 normal control chromosomes Heterozygous g.-3247T>C in <i>cis</i> with p.L445W in families 142 and 264, 5/78 normal control chromosomes
i	107,086,415-107,086,435	F-GTTACTCTTTTGCCTCCTGTTGTTA R-ACAACTCTTTATTGAAGGCATTCTG	
j	107,086,835-107,087,000	F-TTTTGTCTAGTGAGGGAGAGAGAA R-CAACTCCACTACAACAGAGGAAAGT	Heterozygous g.-2393A>C in <i>cis</i> with p.M1T in family 242, 5/104 normal control chromosomes
k	107,087,263-107,087,371	F-TCATTGTAGGATGTTTAGCAGCAT R-TCTCTGAAATGGTAGTCAGCATGT	Heterozygous g.-1952_-1951insT in <i>cis</i> with p.M1T in family 242, 5/110 normal control chromosomes
l	107,087,470-107,087,600	F-CTCCCCTCTTCTCTGTATGTGAATA R-CTCTGTACATCAACCTTCCGTAATC	
m, n	107,087,850-107,088,100	F-AGTTTTAACAAAGTTCATCCCAACA R-GGGACTCCTTAAAGAAGAGCAGAG	
o	107,089,050-107,089,200	F-GTTTGGGGGAGATTCAGAAC R-GAAGAGCGAGGAACAGAAAGAAC	
p	107,090,500-107,090,850	F-TTTTTCTTTCATCTGTAGGTCCTG R-ACAAAGTTATGAACTGGATTCTGCT	
q	107,100,300-107,100,700	F-GTGATCAATTTGACTCCATTTTTG R-TTCTTTCAATCAAAACCTCTTTCTG F-CAAGGTCTTTGAACCTACCATTTA R-TATTTCAAGAGGATCATCGAGGTAG	
r	107,103,950-107,104,350	F-ATGCCTCATTGGATTGTTAAATAAG R-TATGTGTACATGGCCTTACATTGTT F-TATTGGTGAAATGAAATGATTGGAG R-TGTTGACACGTTATTTTTGTATGGT	
s	107,119,750-107,120,000	F-ATGTCCATTCTCCTGATGTTACCT R-AAGTTCCAACATAAGAGAAAACACG	
t	107,121-180-107,121,400	F-ACTCAGACCTTTTGCCTAGACAGT R-CAGCCTGAAACAGTACTATGG	
u	107,125,530-107,125,600	F-CGTGAAAGCTCTATGCTTATCCTAT R-AACAGCCGATTTTGGAAATAAAAAG	
v	107,148,570-107,148,880	F- CCTGGAAGTATTTGGTTGAGTAAGA R- GGCTATGAAAATAAAAATCACATCC	

*Polymorphisms from dbSNP are not included. **Nucleotide numbering was based upon the UCSC version hg18 (March 2006).

Supplementary Table S2. M0 twins.

Family #	213	219 ^a	240	245	261
Zygoty ^b	MZ	DZ	DZ	MZ	DZ
Family history of twinning ^b	Maternal-DZ	Maternal-DZ	No	Maternal-DZ	Maternal-MZ
Assisted reproductive technology	None	None	Clomiphene citrate	None	<i>In vitro</i> fertilization
Paternal age (years) at conception	30	26	37	35	41
Gestational age (weeks) at birth	36	38	37	37	38
Birthweight ^c (lbs)	1: 5 ^{14/16} 2: 5 ^{10/16}	1: 6 ^{9/16} 2: 5 ^{7/16}	1: 6 ^{1/16} 2: 5 ^{6/16}	1: 4 ^{15/16} 2: 4 ^{13/16}	1: 6 ^{8/16} 2: 5 ^{11/16}
Gender ^c	1: female 2: female	1: female 2: female	1: male 2: female	1: female 2: female	1: male 2: female
EVA laterality ^c	1: none 2: left	1: bilateral 2: right	1: none 2: bilateral	1: left 2: left	1: bilateral 2: none
Other health issues ^c	1: none 2: asthma	1: asthma, eczema 2: none	1: none 2: none	1: none 2: exercise- induced asthma	1: seasonal asthma 2: none

^aMother took Tegretol during pregnancy

^bMZ, monozygotic; DZ, dizygotic

^c1, older twin; 2, younger twin